The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
16-Dec-11
$NA
Target:
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
21-Nov-11
$689 million
Target:
iNova Pharmaceuticals
Acquiror:
Valeant Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
07-Nov-11
$398 million
Target:
American Dental Partners, Inc.
Acquiror:
JLL Partners
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
30-Jun-11
$609 million
Target:
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Acquiror:
Royalty Pharma
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
30-Jun-11
$1.7 billion
Target:
Minerva plc
Acquiror:
Jupiter Properties (owned by AREA Property Partners and Delancey Real Estate Asset Mgmt)
Advised Minerva plc, a property investment and development company, on a recommended offer from a consortium consisting of AREA Property Partners and Delancey Real Estate Asset Management
16-Jun-11
$288 million
Target:
Imperial Palace Casino Resort and Spa
Acquiror:
Boyd Gaming Corporation
Advised Boyd Gaming Corporation, a leading gaming operator in Nevada, the Midwest and South, on the acquisition of Imperial Palace Casino Resort and Spa in Biloxi, Mississippi
26-May-11
$192 million
Target:
Centrebet International Limited
Acquiror:
Sportingbet plc
Advised Centrebet International, a leading International online wagering and gaming operator on the recommended cash offer by Sportingbet plc
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
13-Dec-10
$256 million
Target:
Maxinutrition Group Holdings Limited
Acquiror:
GlaxoSmithKline Plc
Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity
07-Dec-10
$500 million
Target:
Medicity, Inc.
Acquiror:
Aetna Inc.
Advised Aetna Inc. on its acquisition of Medicity, Inc., a leading provider of technology solutions to enable the secure access and exchange of healthcare information
26-Nov-10
$118 million
Target:
Healthcare Australia
Acquiror:
Healthcare Locums
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
09-Nov-10
$27.0 billion
Target:
General Growth Properties Inc.
Advised the 2006 Credit Facility Lenders, the largest class of unsecured debt with claims in excess of $2.8 billion, in connection with the Chapter 11 proceedings of mall REIT GGP, which resulted in cash payoff of the facilities in full
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
12-Jul-10
$NA
Target:
Breast Care Business of Ethicon-Endo Surgery
Acquiror:
Devicor Medical Products, Inc. (a GTCR portfolio company)
Advised GTCR and Devicor Medical Products, Inc., a portfolio company of GTCR, on the acquisition of the Breast Care Business of Ethicon-Endo Surgery
10-Jun-10
$580 million
Target:
Tishman Speyer Washington D.C. Portfolio
Advised term loan and credit facility lenders to the Tishman Speyer partnership holding a portfolio of 28 office buildings in Washington D.C. and the surrounding area on a restructuring which resulted in payoff of the facilities in full
05-Apr-10
$225 million
Target:
Medegen, Inc
Acquiror:
CareFusion Corporation
Advised Medegen, Inc., a medical device company that develops, manufactures and markets clinically superior disposable intravenous therapy products on its sale to CareFusion, a global medical devices company
10-Mar-10
$576 million
Target:
Camelot Group plc
Acquiror:
Ontario Teachers’ Pensions Plan
Advised the shareholders of Camelot – Cadbury, De La Rue, Fujitsu, Royal Mail and Thales – on the sale of their shareholdings in Camelot, the operator of the UK National Lottery, to Ontario Teachers’ Pensions Plan
23-Feb-10
$NA
Target:
Heartscape Technologies, Inc.
Acquiror:
Roper Industries, Inc.
Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company
08-Jan-10
$134 million
Target:
Minerva plc
Acquiror:
KiFin Limited
Advised Minerva plc, a UK real estate development company, on its successful defence following an unsolicited offer from KiFin Limited, a company that makes investments for the benefit of Mr Nathan Kirsh
20-Dec-09
$1.3 billion
Target:
Mining Division of Terex Corp.
Acquiror:
Bucyrus International
Advised Bucyrus International, Inc., a global mining equipment manufacturer, on the acquisition of the mining division of Terex Corp., a diversified equipment company
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
08-Oct-09
$455 million
Target:
Ladbrokes Plc
Acted as Joint Financial Adviser to Ladbrokes plc, a leading UK based betting and gaming company, on its rights issue
23-Jun-09
$155 million
Target:
Monogram Biosciences, Inc.
Acquiror:
Laboratory Corporation of America Holdings
Advised LabCorp on the acquisition of Monogram Biosciences, a molecular diagnostics company focused on guiding and improving the treatment of serious infectious diseases and cancer
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
06-Aug-08
$10.7 billion
Target:
Lonmin plc
Acquiror:
Xstrata plc
Advised Lonmin plc, a major producer of Platinum Group Metals, regarding an unsolicited pre-conditional offer for the company by Xstrata plc, a global diversified mining company